secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001193125-24-256654
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres receives Nasdaq bid-price deficiency notice; Q3 net loss $51M from cont. ops; SER-155 shows 77% BSI reduction
--------------------------------------------------------------------------------

- Nasdaq notified Seres (MCRB) that bid price closed below $1.00 for 30 consecutive business days; must regain compliance by May 6, 2025.
- Q3 2024 net loss from continuing ops $51M (vs $41M in Q3 2023); R&D exp $16.5M, G&A $12.7M.
- SER-155 Phase 1b: 77% relative risk reduction in bloodstream infections, lower antibiotic use & febrile neutropenia vs placebo; Breakthrough Therapy requested.
- VOWST sale closed Sep 2024 for ~$175M gross proceeds; expects $50M in Jan 2025 and $25M in Jul 2025; no debt outstanding.
- Cash $66.8M as of Sep 30; expects to fund into Q4 2025 with existing cash and installment payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/0001193125-24-256654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/d912869d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-256654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer